1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Gene Bio Tech Co., Ltd.

Gene Bio Tech Co., Ltd.

KKRX:086060
5,170.00
KRW
+140.00
(+2.78%)
416.78EPS
11.70P/E
41.98BMarket Cap
Gene Bio Tech Co., Ltd.
KRX:086060
(Korea Stock Exchange)

Recent

price

5,170.00

P/E

ratio

11.70

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
3,225.54
4,891.58
10,045.46
8,366.09
7,568.36
6,715.96
6,471.34
6,459.86
7,304.71
6,740.81
6,868.13
7,261.69
9,616.1
9,231.53
9,641.6
10,543.45
10,387.03
Revenue per Share
183
92.22
102
31
160
220
318
243
312
98
-272
-56
177
301
333
440
416.78
Basic EPS, GAAP
80.42
0.35
-600.53
272.65
240.1
215.72
467.24
-8.59
627.62
-577.22
-221.13
-673.73
-563.89
766.8
-191.42
447.65
353.48
Free Cash Flow per Basic Share
50.13
49.16
49.8
26.63
29.91
27.05
29.13
30.05
30.04
29.9
30.01
29.86
- -
- -
- -
- -
- -
Dividend per Share
3,211.46
3,443.33
3,467.8
3,397.97
3,476.83
3,454.56
4,531.87
4,702.18
5,570.29
5,450.16
5,231.12
5,103.62
5,310.44
5,609.93
5,919.73
6,387.01
6,398.56
Book Value per Share
3,206.62
3,282.31
3,307.83
3,260.94
3,343.74
3,348.31
4,428.78
4,598.69
5,470.38
5,346.35
5,139.55
5,012.04
5,195.72
5,536.52
5,844.37
6,319.35
6,332.84
Tangible Book Value per Share
6
6
6
7
7
8
9
9
9
9
9
9
9
9
9
9
9
Basic Weighted Avg Shares
18,788
29,055
58,904
55,037
51,589
52,256
55,632
55,534
62,809
58,245
59,119
62,814
82,759
79,477
82,959
90,789
89,438
Sales/Revenue/Turnover
7.26
4.43
2.17
0.3
1.96
2.04
6.19
4.16
9.98
1.44
2.8
-0.33
2.08
5.05
4.63
4.4
4.48
Operating Margin (%)
1,117
1,113
1,380
1,470
1,425
1,481
1,514
1,507
1,503
1,685
2,047
1,244
1,286
1,338
1,368
1,387
1,384
Depreciation Expense
1,066
548
598
204
1,091
1,712
2,734
2,089
2,683
847
-2,341
-484
1,523
2,591
2,865
3,789
3,589
Net Income, GAAP
48.56
60.62
194.7
- -
70.88
44.03
27.24
19.87
53.09
107.76
- -
- -
16.06
23.2
18.2
14.18
14.67
Effective Tax Rate (%)
5.67
1.89
1.02
0.37
2.11
3.28
4.91
3.76
4.27
1.45
-3.96
-0.77
1.84
3.26
3.45
4.17
4.01
Profit Margin (%)
11,443
11,797
10,812
15,665
11,640
15,803
16,370
18,726
34,101
33,920
32,405
28,037
30,349
34,768
37,472
38,996
39,574
Working Capital
8,273
13,734
11,984
11,445
8,253
8,948
8,744
7,752
8,090
9,564
1,182
2,147
2,342
3,130
2,580
4,848
4,650
LT Debt
18,378
19,480
21,274
23,099
23,420
26,626
36,536
38,056
45,306
43,331
45,043
43,945
45,726
48,305
50,972
54,996
55,095
Total Equity
2.55
1.5
-3.01
- -
0.75
1.54
5.7
3.72
5.32
-0.11
- -
- -
2.5
5.1
4.93
4.92
4.85
Return on Invested Capital (%)
6.6
2.33
0.18
- -
5.88
8.48
7.28
5.19
5.9
2.93
- -
- -
3.11
5.08
5.31
6.24
5.48
Return on Capital (%)
5.8
2.82
2.96
0.94
4.59
6.43
8.06
5.25
6.07
1.78
-5.09
-1.09
3.4
5.51
5.77
7.15
6.72
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
8,686
10,109
11,781
LT Borrowings
5,356
4,782
4,577
LT Finance Leases
84
66
73
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
35,433
34,528
41,977

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
55,194
54,711
59,215
Cash, Cash Equivalents & STI
22,139
24,897
26,501
Accounts Receivable, Net
15,117
12,388
14,470
Inventories
13,896
14,074
15,143
Total Current Liabilities
15,628
15,715
19,641
Payables & Accruals
- -
- -
- -
ST Debt
8,686
10,109
11,781
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.07%
4.13%
7.89%
Free Cash Flow
-813.31%
-101.11%
-334.03%
Net Income, GAAP
-76.13%
-76.17%
32.23%
Sales/Revenue/Turnover
6.15%
9.57%
9.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20,152
20,344
20,435
22,028
82,959
2025
22,846
23,148
24,256
20,539
90,789
2026
21,496
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
81
63
105
83.81
333
2025
89
140.36
114.57
96.23
440
2026
65.62
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
Gene Bio Tech Co., Ltd. is a South Korea-based biotechnology company that engages in the research, development, manufacture, and distribution of functional animal feed additives, veterinary pharmaceuticals, and fermentation-derived bio-products. The company operates primarily through its biotechnology and animal healthcare divisions, providing specialized nutritional and therapeutic solutions for livestock, including swine, poultry, and ruminants. Its core product portfolio comprises fermented vegetable proteins and processed starches, such as Pepsoygen and Bio-Starch; direct-fed microbials and probiotic additives, such as Natufo-Men and Lactocare; non-antibiotic antimicrobial agents, digestive enzymes, and nitrogen-reducing feed additives; veterinary pharmaceuticals, anti-parasitic agents, and deworming formulations, including fenbendazole-based treatments; and biosecurity disinfectants and disease-control chemicals for livestock epidemic prevention. Through its operating subsidiaries, including Woosung Yanghaeng Co., Ltd., Dawon Chemical, and Woosung Transport, the company also provides veterinary medicine compounding, specialized feed packaging, and agricultural logistics services. Gene Bio Tech Co., Ltd. distributes its products domestically across South Korea and exports to global markets, including the United States, Japan, China, Vietnam, and other Southeast Asian countries. In recent developments, the company has expanded its biosecurity and disinfectant product lines to address avian influenza and livestock epidemic prevention, scaled its solid-state fermentation production capacity for next-generation probiotic additives, reinforced veterinary pharmaceutical manufacturing capabilities through its subsidiaries, and expanded overseas commercial partnerships to accelerate export growth. Gene Bio Tech Co., Ltd. was founded in March 2000 and is headquartered in Gongju-si, South Korea.